Literature DB >> 15161053

Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases.

Monika Korabiowska1, Fatima König, Raphaela Verheggen, Thilo Schlott, Carlos Cordon-Cardo, Bernd Romeike, Ulrich Brinck.   

Abstract

Brain metastases, including those of malignant melanoma (known for its high genomic instability), are the most common intracranial tumors. The main objective of this study was to investigate expression and mutation in the DNA mismatch repair system in melanoma brain metastases. Expression of MLH1, MSH2, PMS1 and PMS2 was investigated immunohistochemically in 31 melanoma metastatic tumors. Mutational analysis of MLH1 and MSH2 was performed in 17 melanoma brain metastases. Loss of MLH1 and MSH2 expression was found in 10/31 and 12/31 tumors. PMS1 (27/31) and PMS2 (28/31) expression was preserved in the majority of lesions. Potential missense mutation was found in MSH2 (exon 13) in 2/17 melanomas. Mutation in the intron sequence between exon 14 and 15 of MLH1 (exon 15) was observed in 4/17 cases. Our results indicate that the two major DNA mismatch repair genes, MLH1 and MSH2, are more frequently affected by alterations in the DNA mismatch repair system than the helper genes PMS1 and PMS2. The presence of mutations of MSH2 and MLH1 in melanoma brain metastases, which has not been found in primary melanomas, indicates the high genomic instability of melanoma brain metastases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161053

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  Immune Checkpoint Inhibitors for Brain Metastases.

Authors:  Aaron C Tan; Amy B Heimberger; Alexander M Menzies; Nick Pavlakis; Mustafa Khasraw
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

Review 2.  The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer.

Authors:  Markus Seifert; Jörg Reichrath
Journal:  J Mol Histol       Date:  2006-11-02       Impact factor: 2.611

Review 3.  In vivo animal models for studying brain metastasis: value and limitations.

Authors:  Inderjit Daphu; Terje Sundstrøm; Sindre Horn; Peter C Huszthy; Simone P Niclou; Per Ø Sakariassen; Heike Immervoll; Hrvoje Miletic; Rolf Bjerkvig; Frits Thorsen
Journal:  Clin Exp Metastasis       Date:  2013-01-16       Impact factor: 5.150

4.  Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.

Authors:  Gaurav Sharma; Christine G Lian; William M Lin; Ali Amin-Mansour; Judit Jané-Valbuena; Levi Garraway; Wendi Bao; Charles H Yoon; Nageatte Ibrahim
Journal:  J Cutan Pathol       Date:  2016-06-29       Impact factor: 1.587

Review 5.  MiR-21: an environmental driver of malignant melanoma?

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2015-06-27       Impact factor: 5.531

Review 6.  Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.

Authors:  Ciara C O'Sullivan; Dominic H Moon; Elise C Kohn; Jung-Min Lee
Journal:  Front Oncol       Date:  2014-02-28       Impact factor: 6.244

7.  Characterization of RNA editome in primary and metastatic lung adenocarcinomas.

Authors:  Lihua Peng; Leo J Lee; Heng Xiong; Hong Su; Junhua Rao; Dakai Xiao; Jianxing He; Kui Wu; Dongbing Liu
Journal:  Oncotarget       Date:  2017-02-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.